

Asuragen develops Armored RNA Quant SARS-CoV-2 control

April 16, 2020—[Asuragen](#) has developed an Armored RNA Quant SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic.

The Armored RNA Quant SARS-CoV-2 Control targets the SARS-CoV-2 viral nucleocapsid (N) region and, along with the company's RNase P construct, aligns with the CDC- and WHO-recommended Diagnostic Panel (CDC-006-00019), the company says. Armored technology encapsulates the in vitro transcribed RNA in a protective protein coat to resist nuclease degradation.